Efficacy of depot long‐acting release octreotide therapy in severe dumping syndrome
Open accessAbstract
Summary: Background: Dumping syndrome is a serious complication occurring in 10% of patients after gastric surgery. Dumping symptoms are effectively reduced by subcutaneous application of the somatostatin analogue octreotide, but side‐effects limit its use. Aim: To evaluate the efficacy of depot long‐acting release octreotide (Sandostatin‐LAR) vs. octreotide subcutaneous on dumping symptoms, quality of life and side‐effects. Methods: Twelve patients (five females, age 58 ± 3 years) with severe dumping symptoms, requiring daily use of octreotide subcutaneous, were included in an open study and changed from octreotide subcutaneous after a 2 weeks washout to Sandostatin‐LAR 10 mg i.m., every 4 weeks for 6 months. Symptoms (diary), body weight, fat excretion, food intake and Gastrointestinal Specific Quality of Life Index were evaluated. Results: Gastrointestinal Specific Quality of Life Index increased significantly (P < 0.05) during Sandostatin‐LAR treatment (88 ± 4) compared with octreotide (74 ± 4) and washout (75 ± 6). During Sandostatin‐LAR treatment, abdominal symptom score was lower compared with octreotide and washout, but not significantly. During Sandostatin‐LAR treatment, body weight increased (66 ± 4 to 70 ± 3 kg; P = 0.19). Conclusions: Sandostatin‐LAR is at least as effective as octreotide subcutaneous in suppressing symptoms in patients with severe dumping syndrome and is more effective than octreotide subcutaneous in increasing body weight and quality of life.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Long-acting somatostatin analogue formulations are preferred by patients over short-acting formulations because of less frequent administration and associated improvements in quality of life.
“Long-acting formulations are preferred by patients because of less frequent administration and the associated improvements in quality of life (15,89).”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [89]
The Introduction says monthly long-acting octreotide replaces daily injections, and the Quality of life section reports significantly higher quality-of-life scores during long-acting treatment. The paper does not report measuring patient preference or establish that less frequent administration caused the quality-of-life improvement; the Discussion says the significant subscale improvement was in gastrointestinal symptoms. Page numbers are unavailable in our copy. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 21
- Vecht J, Masclee AA, Lamers CB. The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment. Scand J Gastroenterol Suppl 1997; 223: 21-7.
- Lyons TJ, McLoughlin JC, Shaw C, Buchanan KD. Effect of acarbose on biochemical responses and clinical symptoms in dumping syndrome. Digestion 1985; 31: 89-96.
- Hopman WP, Wolberink RG, Lamers CB, Van Tongeren JH. Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995. Ann Surg 1988; 207: 155-9.
- Tulassay Z, Tulassay T, Gupta R, Cierny G. Long acting somatostatin analogue in dumping syndrome. Br J Surg 1989; 76: 1294-5.
- Geer RJ, Richards WO, O'Dorisio TM, et al. Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome. Ann Surg 1990; 212: 678-87.
- Richards WO, Geer R, O'Dorisio TM, et al. Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. J Surg Res 1990; 49: 483-7.
- Kooner JS, Peart WS, Mathias CJ. The peptide release inhibitor, octreotide (SMS 201-995), prevents the haemodynamic changes following food ingestion in normal human subjects. Q J Exp Physiol 1989; 74: 569-72.
- Hasler WL, Soudah HC, Owyang C. Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. J Pharmacol Exp Ther 1996; 277: 1359-65.
- Gray JL, Debas HT, Mulvihill SJ. Control of dumping symptoms by somatostatin analogue in patients after gastric surgery. Arch Surg 1991; 126: 1231-5; discussion 35-6.
- Vecht J, Lamers CB, Masclee AA. Long-term results of octreotide-therapy in severe dumping syndrome. Clin Endocrinol (Oxf) 1999; 51: 619-24.
- Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996; 45: 67-71.
- Mangupli R, Lisette A, Ivett C, Paul C, de los Rios Victoria C, Luis CJ. Improvement of acromegaly after octreotide LAR treatment. Pituitary 2003; 6: 29-34.
- Nehra V, Camilleri M, Burton D, Oenning L, Kelly DG. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol 2001; 96: 1494-8.
- Arnold R, Frank M. Gastrointestinal endocrine tumours: medical management. Baillieres Clin Gastroenterol 1996; 10: 737-59.
- Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003; 17: 437-44.
- van der Kleij FG, Vecht J, Lamers CB, Masclee AA. Diagnostic value of dumping provocation in patients after gastric surgery. Scand J Gastroenterol 1996; 31: 1162-6.
- Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995; 82: 216-22.
- van de Kamer JH, Huinink HTB, Weyers HA. Rapid method for determination of fat in feces. J Biol Chem 1949; 177: 349-55.
- Kamoi K, Miyakoshi M, Maruyama R. A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR- QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2004; 64: 19-25.
- Freda PU, Reyes CM, Conwell IM, Sundeen RE, Wardlaw SL. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. J Clin Endocrinol Metab 2003; 88: 2037-44.
- Norrelund H, Hansen TK, Orskov H, et al. Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. Clin Endocrinol (Oxf) 2002; 57: 539-46.
Cited by
Sorted by citations
Pathophysiology, diagnosis and management of postoperative dumping syndrome
Tack, J., Arts, J., Caenepeel, P., De Wulf, D., & Bisschops, R. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.148 · Cited by 387 · see citing works
van Beek, A. P., Emous, M., Laville, M., & Tack, J. (2017) · Obesity Reviews · doi:10.1111/obr.12467 · Cited by 288 · see citing works
“(89) Single-arm, open-label study N = 12 Octreotide LAR 10 mg every 4 weeks for”
Background
- Authors
- PENNING, C., VECHT, J., & MASCLEE, A. A. M.
- Affiliations
- Leiden University Medical Center (NL)
- Isala (NL)
- Corresponding author
- MASCLEE, A. A. M.
- ORCID
- MASCLEE, A. A. M.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-10-21
- Volume
- 22
- Issue
- 10
- Pages
- 963-969
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2018202279
- Cited by
- 48
- References
- 0
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 4 · 2019: 3 · 2018: 3 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 4 · 2012: 1
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharma
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Bleeding Diagnosis and Treatment
- Keywords
- dumping syndrome, octreotide, Sandostatin LAR, somatostatin analogues, gastric surgery complications, quality of life, body weight, fat excretion, abdominal symptoms, adverse drug reactions
- MeSH terms
- Body Weight, Chronic Disease, Delayed-Action Preparations, Dumping Syndrome, Female, Gastrointestinal Agents, Humans, Injections, Subcutaneous, Male, Middle Aged, Quality of Life, Octreotide, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
